BOSTON — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the Neuromuscular and Bone Panel presentation at the...
Latest News
BOSTON, Mass. — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time. During the conference...
Okayama, Japan – Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor functions, which eventually leads to death within 5 years of its onset. This disease causes weakness and atrophy of limbs and other muscles, which affect mobility speech, eating, and even breathing in patients....
The cellular glitches underlying a rare genetic disorder called activated PI3K Delta syndrome 2 (APDS2) have been identified by researchers at the Garvan Institute of Medical Research. The disorder is caused by genetic variations that disrupt immune cell signalling through a protein called PI3K. “This study tells us how signalling...
Hong Kong – Artificial intelligence is a growing presence in biopharma, with applications beyond the discovery apparatus. It was a hot-button issue in San Francisco last week as the industry gathered around the annual JP Morgan Healthcare Conference. Eli Lilly and Novartis even announced multi-million-dollar discovery deals with Alphabet’s Isomorphic...
Rockville, Maryland – Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially first-in-class poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD). Designed and developed by Insilico’s proprietary end-to-end AI...
Executives from clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine will present on the impact of AI on biotechnology at the Future Investment Initiative (FII) Conference in Riyadh, Saudi Arabia. Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine and Petrina Kamya, PhD, Head of AI Platforms and...
Hong Kong – Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1....
BRIDGEWATER, N.J — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of...
Bridgewater, N.J. — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee and...